Screener
Opus Genetics IRD Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Opus Genetics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034084
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash provided by financing activities | 27,595 | 20,465 |
| Net increase in cash and cash equivalents | 14,868 | 11,471 |
| Cash and cash equivalents at beginning of period | 45,091 | 30,321 |
| Cash and cash equivalents at end of period | $59,959 | $41,792 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for income taxes | — | — |
| Cash paid for interest | — | — |
| Supplemental non-cash financing transactions: |
Item 1. Financial Statements
FAQ
- What is Opus Genetics's cash & equivalents?
- Opus Genetics (IRD) reported cash & equivalents of $59.96M in Q1 2026.
- How has Opus Genetics's cash & equivalents changed year-over-year?
- Opus Genetics's cash & equivalents increased by 43.5% year-over-year, from $41.79M to $59.96M.
- What is the long-term trend for Opus Genetics's cash & equivalents?
- Over 5 years (2020 to 2025), Opus Genetics's cash & equivalents has grown at a 22.4% compound annual growth rate (CAGR), from $16.4M to $45.09M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Opus Genetics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude